TRIAL NEW TB
DRUGS BEGINS OCTOBER
The
new TB (Tuberculosis) drug which is likely to shorten the duration of treatment
and be more effective will start with clinical trials in October in Bagamoyo
District.
Hitherto,
full treatment of this killer disease took almost six-to-eight months and
recently conventional drugs did not appear to be 100% effective. The new
medicine is likely to shorten the span of treatment, possible by more than 50%
and may likely replace the old drugs.
In
order to arrive to a scientific conclusion of the new TB drug, a community
based well-knitted team work, assembled at the
Bagamoyo Branch of Ifakara Health Institute for a “brush-up” seminar on
Wednesday morning. Almost eighty people attended the instructions delivered by
Coordinator of the project Dr. Omar Juma, the project team leader Dr. Thomas
Zoller, Dr. Mwinyi Kambi Salum and Lab Technicians.
The
delegates were drawn from National Tuberculosis & Leprosy Programme; IHI
staff and scientists; Community Advisory Board members from 24 villages in
Bagamoyo District; Health Workers, Artists & Singers who will portray the
campaign. They will all play their respective roles in locating and managing
the treatment of TB Patients in Bagamoyo District covering a study area of 1160
km2 in 24 villages. The study area has a total of administrative
demarcated offices of 3 Division, 8
Wards and 24 Village Governments.
Speaking
politely but firmly, he asked the entire team to look at the whole exercise
seriously with a positive end result. He mentioned, among others, three major
points which were: (a) implementation of new diagonistic methods to speed-up
the exercise; (b) to get all the team members to work seriously; (d) to analyze
the effectiveness of the new TB drug in comparison to the conventional medicines.
For
information: TB is one of the world’s deadliest pandemic diseases and is
increasingly resistant to current drugs. TB is the leading infectious killer of
people with HIV/AIDS disease. TB kills someone approximately every 20 seconds,
or 4100 every day. Nearly 1,500,000 were reported to have died of TB in 2013
throughout the world.
Dr.
Thomas Zoller a Scientist from Germany and who is the Project Leader of the new
TB drug speculated that with a properly laid ground work, location of TB patients
through laboratory investigations and full treatment will surely result
positively.
For information: The
Bagamoyo Branch of Ifakara Health Institute was established in 2005 as a site
for malaria drug and vaccine clinical trials. Recently it expanded the services
to cover TB and HIV/AIDS related research work. It is financed by TB Alliance
with active support from various organizations including Australia, USA, Bill
and Melinda Gates Foundation, European Commission, Global Health Innovation
Tech. Fund, National Institute of Allergy & Infectious Disease, UNITAID, UK
Department for International Aid, US Food & Drug Administration.
Story &
Pictures by Abdul Hai
Bagamoyo News
Team Leader of the new TB Drug clinical trials at IHI Bagamoyo, Dr. Thomas Zoller and Coordinator of IHI Dr. Omar Juma speaking to over 80 delegates who attanded the seminar at Bagamoyo on Wednesday. |
A group picture of the participants who attended the one-day seminar to effectively manage the clinical trials of the new TB Drug which will begin in October this year. |
Participants listening attentively to the Lecturer Dr. Omar Juma in the conference room of IHI Bagamoyo. |
Health Workers, Artists, Lab Technicians, Community Advisory Board Members listening to the lectures at the one-day seminar held in Bagamoyo. |